GET DAILY SIGNALSMcKesson (MCK) Delivers Strong Q2 Fiscal 2027 Results with +18% EPS Growth
Key Takeaways
- McKesson reported adjusted EPS (earnings per share) of $11.68 for the second quarter of fiscal 2027, up 18% year over year and above the consensus estimate of roughly $10.71.
- Consolidated revenue rose 8% to approximately $111 billion ($110.96 billion), topping the roughly $109.86 billion analyst consensus.
- The company raised its full-year fiscal 2027 adjusted EPS guidance to $45.60–$46.40, up from a prior range of $44.20–$45.00.
- Growth was led by specialty distribution and GLP-1 (glucagon-like peptide-1) medication volumes; GLP-1 distribution revenue reached $16 billion, up 26% year over year.
- Medical-Surgical Solutions adjusted operating profit declined 10%, reflecting lower contributions from the ambulatory care channel due to product mix.
- McKesson announced a roughly $1.4 billion minority investment in Option Care Health and completed its approximately $2.25 billion acquisition of Precision Medicine Group.
Earnings Context and Why It Matters
McKesson Corporation is one of the largest pharmaceutical distributors in the United States, so its quarterly results provide useful insight into healthcare supply-chain trends, prescription volumes, specialty drug demand, and payer dynamics. The fiscal second quarter ended September 30, 2026, arrives at a time when specialty therapies and GLP-1 medications continue to influence distribution patterns. Since McKesson uses a fiscal year ending March 31, this report marks the midpoint of fiscal 2027 and serves as an important checkpoint for the company’s full-year outlook. I find these updates particularly relevant because they help show whether growth in higher-margin specialty and oncology services can continue to offset pressures from branded-to-generic shifts and pharmaceutical pricing.
Reported Results
McKesson posted second-quarter fiscal 2027 adjusted EPS of $11.68, representing an 18% rise from $9.86 in the prior-year quarter and comfortably ahead of the consensus estimate near $10.71. Consolidated revenue increased 8% to roughly $111 billion ($110.96 billion), surpassing the analyst consensus of about $109.86 billion. The company does not provide GAAP-based forward guidance due to the challenges in forecasting certain items. Gross profit climbed 10% to $3.9 billion, and operating profit rose 13% to $1.9 billion, supported by operating leverage and a reduced share count. Segment performance included North American Pharmaceutical revenue up 6% to $91.4 billion with adjusted operating profit advancing 22% to $1.0 billion, while Oncology & Multispecialty revenue surged 24% to $15.0 billion and Prescription Technology Solutions revenue grew 10% to $1.5 billion. Medical-Surgical Solutions revenue rose 5% to $3.1 billion, although its adjusted operating profit fell 10% to $225 million. Management lifted fiscal 2027 adjusted EPS guidance to $45.60–$46.40 from the previous $44.20–$45.00 range and above the consensus near $44.66, citing broad business strength and execution confidence. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
McKesson shares responded positively, closing at $1,069.44 for an approximate 7% gain on the day as investors welcomed the earnings beat and the raised full-year guidance. The results underscored ongoing demand for specialty pharmaceuticals, oncology services, and GLP-1 therapies as a reliable growth driver. Additional support came from the extension of the pharmaceutical distribution partnership with CVS Health through June 2032 and moves into community-based specialty care. The Medical-Surgical Solutions segment remains the primary focus of scrutiny, where product mix weighed on profitability despite revenue growth.
Forward Outlook and Key Factors to Monitor
With the guidance increase in place, attention now turns to whether McKesson can maintain specialty-led momentum through the second half of fiscal 2027. The completed Precision Medicine Group acquisition is projected to add roughly $0.10–$0.20 to adjusted EPS in fiscal 2027, with most of the impact expected in the fourth quarter, and management anticipates accretion of about $1.60–$1.80 by the end of year three. Investors will also follow the planned $1.4 billion investment for a 49% stake in Option Care Health, slated to close in the first half of calendar 2027, along with the ongoing separation of the Medical-Surgical Solutions business. On the demand side, GLP-1 volumes stay robust, although management highlighted some quarter-to-quarter variability linked to payer dynamics and patient utilization. Additional items to watch include the pace of branded-to-generic conversions, branded pharmaceutical pricing changes, expense management, and share repurchases that continue to lower the diluted share count and support per-share growth. These factors will determine if McKesson can sustain its operating leverage and meet the updated full-year targets.
Using Tickeron’s AI Screener in My Analysis
In my research process, I often turn to Tickeron’s AI Screener for deeper insights. It helps filter stocks and ETFs by technical patterns, fundamentals, trends, and performance metrics, which can surface relevant trade ideas and sector comparisons more efficiently than manual reviews. This tool has become a practical part of how I cross-check earnings-focused names like McKesson against peers in healthcare distribution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for MCK shows an upward move is likely
MCK's Aroon Indicator triggered a bullish signal on October 29, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 355 similar instances where the Aroon Indicator showed a similar pattern. In 254 of the 355 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on MCK as a result. In 61 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for MCK just turned positive on November 04, 2026. Looking at past instances where MCK's MACD turned positive, the stock continued to rise in 32 of 52 cases over the following month. The odds of a continued upward trend are 62%.
MCK moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MCK crossed bullishly above the 50-day moving average on October 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +7.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in 253 of 381 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
MCK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-29.407) is normal, around the industry mean (13.339). MCK has a moderately high P/E Ratio (28.564) as compared to the industry average of (10.779). Projected Growth (PEG Ratio) (1.616) is also within normal values, averaging (2.016). Dividend Yield (0.004) settles around the average of (0.134) among similar stocks. P/S Ratio (0.265) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors
Advertisement